This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McInnes, G. T Search for Related Content PubMed PubMed Citation Articles by McInnes, G. T Social Bookmarking                         What's this?

Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy

University of Glasgow, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK, g.t.mcinnes{at}clinmed.gla.ac.uk

Prospective randomised trials have demonstrated convincingly the benefits of drug treatment of hypertension. Treatment with conventional antihypertensive agents reduces the incidence of cardiovascular events by about that which would be expected from epidemiological data for the achieved difference in blood pressure. Newer agents, such as angiotensin II receptor blockers, have potential for benefits beyond blood pressure reduction. This rationale is under evaluation in a number of long-term morbidity and mortality trials which will report over the next few years, with the largest, VALUE, due to provide results in 2004. The findings from these trials will be decisive in determining the future role of this important new class of drugs.

Key Words: angiotensin receptor blockers • coronary heart disease • long-term mortality trials • LIFE • SCOPE • valsartan • VALUE

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S17-S20 (2000)
DOI: 10.3317/jraas.2000.048


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?